Hers vs MEDVi: Which GLP-1 Provider Is Better?
Short answer: Hers scores higher on our rubric, 7.3/10 against 5.7/10. Full reasoning, pricing and the cases where the other one wins are below.
Hers beats MEDVi overall, scoring 7.3/10 vs 5.7/10. Published pricing is not a like-for-like monthly comparison: Hers is $188 first month, then $298/mo; MEDVi is $179 first month, then $299/mo. Choose Hers for women who want a female-focused platform and can budget at least $188 initially and $298/mo ongoing for a $149 medication path. Choose MEDVi for users who want both oral and injectable compounded options in one telehealth program.
A side-by-side look at Hers and MEDVi to help you decide. We compare them on:
- •Starting price per month
- •Our overall score, out of 10
- •Medication type, brand-name or compounded
- •Whether they accept insurance
- •Who each one is best for
Hers
#30 of 54The women's health arm of Hims & Hers Health (NYSE: HIMS). Hers lists Wegovy pill, Foundayo, and Ozempic pill medication from $149, a Wegovy pen from $199, Zepbound from $299, and compounded options. A required Weight Loss Membership adds $39 in month one and $149/mo thereafter, so the all-in floor for a $149 medication path is $188 initially and $298/mo ongoing; exact product and dose prices vary.
Visit HersMEDVi
#46 of 54MEDVi offers oral and injectable compounded GLP-1 care. Semaglutide is $179 for month one and $299 for refills. Trustpilot is 4.4/5 across roughly 11,000 reviews, while BBB is F/not accredited. FDA warning letter #721455 concerns misleading labeling and marketing, not an allegation that the medication was unsafe.
Visit MEDVi| Feature | Hers | MEDVi |
|---|---|---|
| Why each one | A major women-focused telehealth platform with a direct Novo Nordisk partnership (Wegovy pill from $149 and pen from $199 before required membership) and a Lilly partnership (Zepbound medication from $299) alongside compounded options. | Oral and injectable compounded formats in one program, with micro-dosing options and a path to FDA-approved brand medication. |
| Our Score | 7.3/10 | 5.7/10 |
| Headline Price | $188 first month, then $298/mo | $179 first month, then $299/mo |
| Medication Type | Both | Both |
| Insurance Accepted | No | No |
| Best For | Women who want a female-focused platform and can budget at least $188 initially and $298/mo ongoing for a $149 medication path | Users who want both oral and injectable compounded options in one telehealth program |
| Watch out for | Pending federal enforcement action against the parent company. On July 29, 2026 the FTC, joined by Utah and California acting through Los Angeles County Counsel, filed a complaint against Hims & Hers Health, Inc. in the U.S. District Court for the Northern District of California, alleging violations of the FTC Act and the Restore Online Shoppers' Confidence Act over subscription billing, cancellation friction, and sharing consumer health information with advertising platforms. Case status is Pending. These are allegations, not findings. | FDA warning letter #721455, issued February 20, 2026, cites misleading labeling and marketing that implied MEDVi compounded the drugs and that compounded products were equivalent to or FDA-evaluated like approved brands. The letter does not allege unsafe medication |
| Ranking | #30 | #46 |
| Get started | Visit Hers | Visit MEDVi |
Pros & Cons Compared
Hers
Pros
- +FDA-approved brand paths include Wegovy pill, Foundayo, and Ozempic pill medication from $149 and a Wegovy pen from $199; with the required membership, a $149 medication path totals $188 initially and $298/mo ongoing
- +Zepbound access via the Lilly/Hims-Hers partnership announced 2026
- +Publicly traded company (NYSE: HIMS) with strong financial backing and regulatory compliance
- +Broader women's health platform, integrates weight loss with hormonal, skin, and wellness services
Cons
- −Pending federal enforcement action against the parent company. On July 29, 2026 the FTC, joined by Utah and California acting through Los Angeles County Counsel, filed a complaint against Hims & Hers Health, Inc. in the U.S. District Court for the Northern District of California, alleging violations of the FTC Act and the Restore Online Shoppers' Confidence Act over subscription billing, cancellation friction, and sharing consumer health information with advertising platforms. Case status is Pending. These are allegations, not findings.
- −Every medication figure excludes the required Weight Loss Membership ($39 first month, then $149/mo); exact product and dose prices can increase the total above the $188/$298 floor
- −Support runs at big-platform scale, fine for routine refills, less personal if you want high-touch care
- −Compounded pricing starts at $199/mo with stepped pricing at higher doses, budget for the dose you'll end up on, not the entry dose
- −Zepbound medication starts at $299 before the required membership; that path totals $338 in month one and at least $448/mo ongoing, with exact dose pricing potentially higher
MEDVi
Pros
- +One of the few compounded providers offering both oral tablets and injectable semaglutide
- +Micro-dosing options available, can start at sub-standard doses for patients concerned about side effects
- +Sleek onboarding experience with clear progress tracking through their patient portal
- +$179 covers the first month of compounded semaglutide on the current Katalys landing, including clinician review, medication and shipping
Cons
- −FDA warning letter #721455, issued February 20, 2026, cites misleading labeling and marketing that implied MEDVi compounded the drugs and that compounded products were equivalent to or FDA-evaluated like approved brands. The letter does not allege unsafe medication
- −Its third-party records conflict: 4.4/5 across roughly 11,000 Trustpilot reviews, but an F and no accreditation at the BBB
- −The $179 semaglutide price is introductory; the current Katalys landing says refills are $299/mo, making the first-year total $3,468 rather than $2,148
- −Brand-name Wegovy and Zepbound paths add a $99 membership plus the medication cost, which the current landing does not publish; availability can change
- −No insurance accepted, and oral compounded semaglutide has less clinical data than injectable forms
Our Verdict
Hers edges out MEDVi with a score of 7.3/10 vs 5.7/10. Published pricing is not a like-for-like monthly comparison: Hers is $188 first month, then $298/mo; MEDVi is $179 first month, then $299/mo.
Read Full Reviews
Related comparisons
More head-to-head comparisons involving Hers and MEDVi.
Not comparing, just asking? Quick answers to the most-asked GLP-1 questions →
- Hers vs Galafrom $149/mo
- Hers vs Oak Longevityfrom $119/mo
- Hers vs Fridays$249/mo month-to-month
- MEDVi vs Noom Med$79 first month, then $199/mo
- MEDVi vs GobyMedsfrom $99/mo
- MEDVi vs Lemonaid Healthpublished $129/mo; total not verified
Not sure which one is right for you?
Answer a few quick questions and we'll match you to the best GLP-1 provider for your needs. Or keep exploring below.
Our pick of these two: Hers · 7.3/10